Induction of cellular immunity in a parathyroid carcinoma treated with tumor lysate-pulsed dendritic cells

European Journal of Endocrinology

Volumn 142, Issue 3, 2000, Pages 300-306

  Schott, Matthias ^a   Feldkamp, Joachim ^a   Schattenberg, Dirk ^a   Krueger, Thilo ^a   Dotzenrath, Cornelia ^a   Seissler, Jochen ^a   Scherbaum, Werner A ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN;

ADULT; ARTICLE; CASE REPORT; CELL LYSATE; CELLULAR IMMUNITY; DENDRITIC CELL; FEMALE; HUMAN; HUMAN CELL; IMMUNIZATION; PARATHYROID CARCINOMA; PARATHYROID DISEASE; PRIORITY JOURNAL; TREATMENT OUTCOME; VACCINATION;

EID: 0034108143     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/eje.0.1420300     Document Type: Article

References (24)

1. Ellenhorn JD, Schreiber H & Bluestone JA. Mechanism of tumor rejection in anti-CD3 monoclonal antibody-treated mice. Journal of Immunology 1990 144 2840-2846.
2. + T lymphocytes in the primary and memory response to nonimmunogenic murine mammary adenocarcinoma made immunogenic by IL-2 gene. Journal of Immunology 1992 149 3627-5655.
3. Huang AY, Golumbek P, Ahmadzadeh M, Jaffee E, Pardoll D & Levitsky H. Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science 1994 264 961-965.
4. Cayeux S, Richter G, Becker C, Beck C, Aicher A, Pezzutto A, Dorken B & Blankenstein T. Lack of correlation between rejection of tumor cells co-expressing interleukin-2 and B7.1 and vaccine efficiency. European Journal of Immunology 1997 27 1657-1662.
5. Ashwell JD. Are B lymphocytes the principal antigen-presenting cells in vivo? Journal of Immunology 1990 140 5697-3700.
6. Qin Z, Richter G, Schuler T, Ibe S, Cao X & Blankenstein T. B cells inhibit induction of T cell-dependent tumor immunity. Nature Medicine 1998 4 627-650.
7. Steinman RM. The dendritic cell system and its role in immunogenicity. Annual Review of Immunology 1991 9 271-296.
8. Inaba K, Pack M, Inaba M, Sakuta H, Isdell F & Steinman RM. High levels of a major histocompatibility complex II-self peptide complex on dendritic cells from the T cell areas of lymph nodes. Journal of Experimental Medicine 1997 186 665-672.
9. Caux C, Vanbervliet B, Massacrier C, Azuma M, Okumura K, Lanier LL & Banchereau J. B70/B7-2 is identical to CD86 and is the major functional ligand for CD28 expressed on human dendritic cells. Journal of Experimental Medicine 1994 180 1841-1847.
10. Inaba K, Witmer PM, Inaba M, Hathcock KS, Sakuta H, Azuma M, Yagita H, Okumura K, Linsley PS & Ikehara S. The tissue distribution of the B7-2 costimulator in mice: abundant expression on dendritic cells in situ and during maturation in vitro. Journal of Experimental Medicine 1994 180 1849-1860.
11. + cytotoxic T lymphocytes by immunization with syngeneic irradiated HIV-1 envelope derived peptide-pulsed dendritic cells. International Immunology 1995 5 849-857.
12. Ashley DM, Faiola B, Nair S, Hale LP, Bigner DD & Gilboa E. Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induce antitumor immunity against central nervous system tumors. Journal of Experimental Medicine 1997 186 1177-1182.
13. Specht JM, Wang G, Do MT, Lam JS, Royal RE, Reeves ME, Rosenberg SA & Hwu P. Dendritic cells retrovirally transduced with a model antigen gene are therapeutically effective against established pulmonary metastases. Journal of Experimental Medicine 1997 186 1213-1221.
14. Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, Burg G &Schadendorf D. Vaccination of melanoma patients with peptide-or tumor lysate-pulsed dendritic cells. Nature Medicine 1998 4 328-332.
15. Tjoa BA, Simmons SJ, Bowes VA, Ragde H, Rogers M, Elgamal A, Kenny KM, Cobb OE, Ireton RC, Troychak MJ, Salgaller ML, Boynton AL & Murphy GP. Evaluation of phase I/II clinical trials in prostate cancer with dendritic cells and PSMA peptides. Prostate 1998 36 39-44.
16. Romani N, Gruner S, Brang D, Kampgen E, Lenz A, Trockenbacher B, Konwalinka G, Fritsch PO, Steinman RM & Schuler G. Proliferating dendritic cell progenitors in human blood. Journal of Experimental Medicine 1994 180 83-93.
17. Sallusto F & Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. Journal of Experimental Medicine 1994 179 1109-1118.
18. Alijagic S, Moller P, Artuc M, Jurgovsky K, Czarnetzki BM & Schadendorf D. Dendritic cells generated from peripheral blood transfected with human tyrosinase induce specific T cell activation. European Journal of Immunology 1995 25 3100-3107.
19. Ludewig B, Graf D, Gelderblom HR, Becker Y, Kroczek RA & Pauli G. Spontaneous apoptosis of dendritic cells is efficiently inhibited by TRAP (CD40-ligand) and TNF-alpha, but strongly enhanced by interleukin-10. European Journal of Immunology 1995 25 1943-1950.
20. Shane E & Bilezikian JP. Parathyroid carcinoma: a review of 62 patients. Endocrine Review 1982 3 218-226.
21. Bukowski RM, Sheeler L, Cunningham J & Esselstyn C. Successful combination chemotherapy for metastatic parathyroid carcinoma. Archives of Internal Medicine 1984 144 399-400.
22. Calandra DB, Chejfec G, Foy BK, Lawrence AM & Paloyan E. Parathyroid carcinoma: biochemical and pathologic response to DTIC. Surgery 1984 96 1132-1137.
23. Hsu FJ, Benike C, Fagnoni F, Liles TM, Czerwinski D, Taidi B, Engleman EG & Levy R. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nature Medicine 1996 2 52-58.
24. Bradwell AR & Harvey TC. Control of hypercalcaemia of parathyroid carcinoma by immunisation. Lancet 1999 353 370-373.